ArticleBlood advances2023

Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma.

Kunal C Potnis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.